Trends in prescription drug use from 1980 – 2018

Trends in prescription drug use from 1980 – 2018

We are living in a future that our great-grandparents could only dream of.

High blood pressure? There are medicines for that. Depression and anxiety? Cheap prescription pills make a huge difference. High cholesterol, ulcers, acid reflux, heart disease and even hepatitis C? All just a co-pay away from meaningful treatment for many Americans.

It’s no surprise that we are taking more prescription medicine that ever before, as treatments once non-existent and, then, very expensive, have become available to the masses, with or without a formal prescription drug insurance plan.

How did we get here? For answers, we look to the landmark study Prescription Drugs: Spending, Use, and Pricesreleased in 2022 by the non-partisan Congressional Budget Office (CBO). The study looks at prescription cost and access from 1980 to 2018.

Some of the CBO’s keenest insights are around the hows and whys of our explosion of beneficial prescription drug use.

Trends in the use of prescription drugs

According to the CBO report, “utilization of prescription drugs nationwide has increased in recent years, both because the prevalence of chronic conditions has increased with the aging of the U.S. population and because new therapies and generic drugs have become available.

“Over the past several decades, consumers, health care providers, and insurers have witnessed the emergence of blockbuster therapies that treat common conditions; and the emergence of generic alternatives for those drugs has improved access to such treatments by offering lower-cost options. In addition, consumers’ share of spending on prescription drugs has fallen substantially as the combined share of spending covered by federal programs and private health insurance has increased over time. 

“Use of prescription drugs among those enrolled in Medicare Part D and Medicaid increased as well. Administrative data about Medicare Part D show that from 2009 to 2018 the average number of standardized prescriptions per beneficiary rose from 48 to 54 per year—a 13 percent increase.”

Underlying drivers of increased prescription drug use 

The reduction in consumers’ out-of-pocket costs for prescription drugs is one key factor that explains the increased use of prescription drugs. In 1990, consumers’ share of spending on prescription drugs was 57 percent. By 2009, that share had fallen to 20 percent. It continued to fall thereafter, declining to 15 percent in 2018. That long-term decline is largely explained by a gradual increase in the share of spending covered by the Medicare and Medicaid programs, which grew from 13 percent in 1990 to 36 percent in 2018.

Some of that increase is attributable to the creation of Medicare Part D in 2006. In that year, the share of spending covered by Medicare and Medicaid increased to 25 percent, up from 19 percent in 2005. That share has steadily increased since 2006. More recent increases were partly attributable to the increased generosity of the Part D benefit that was mandated by both the ACA in 2010 and the Bipartisan Budget Act of 2018, as well as to the Medicaid expansions that were encouraged by the ACA.

Greater access to generic drugs in those programs may be another key factor that explains the increased use of prescription drugs: Lower-cost options make it easier for people to purchase their prescribed medications. Nationwide, the share of standardized prescriptions dispensed for generic drugs was 75 percent in 2009 and reached 90 percent by 2018. 

In 2022, the non-partisan Congressional Budget Office (CBO) of the United States issued a landmark study that tracks the use of prescription drugs, their costs and their benefits.

In the overview article, we look at the general trends identified by the CBO over the past 40 years. Subsequent articles dive in deeper        

Read more:

VativoRx Joins MHA: A New Chapter Begins

The world of healthcare is dynamic, continuously evolving with new challenges and opportunities. At VativoRx, we’ve always believed in the power of innovation, collaboration, and dedication to ensure that we provide the best rebate management solutions in the industry. Today, we’re thrilled to announce our latest milestone: VativoRx is now an official associate member of the Michigan Health & Hospital Association (MHA)!

Read More »

Unveiling the Future: Navigating the Evolving Landscape of 340B Rebates.

The 340B Drug Pricing Program, established in 1992, has been a crucial component of the healthcare system, dedicated to assisting eligible healthcare organizations in serving vulnerable patient populations by granting them access to discounted drugs. At the heart of this program are the 340B rebates, which enable qualifying entities such as safety-net hospitals, community health centers, and other eligible providers to acquire medications at significantly reduced prices.

Read More »
Martin Shields / Alamy Stock Photo

Humira – The End of an Era

In January 2023, the first biosimilar version of Humira, which is a widely used injectable drug for inflammatory diseases, was approved, marking the end of AbbVie’s two-decade market exclusivity. Humira is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and it works by targeting certain proteins in the immune system.

Read More »

Biosimilars — Similar But Not Identical

You may have never heard of biosimilar drugs and that’s probably because they are not commonly prescribed in the United States even though they have been around for over 20 years. So, what are biosimilar drugs? A biosimilar drug is no different in terms of safety and effectiveness than a biologic product, also known as a reference product, and while highly similar it is not identical.

Read More »

Lower Cost Prescription Drugs from Canada, Is It Legal?

In the early 2000s, the FDA set up guidelines in the Regulatory Procedures Manual (RPM) that permitted prescription drugs to be imported from other countries if the patient met very strict guidelines. Just stating that the patient needed the drug due to cost savings was not a justification to obtain the drug.

Read More »